Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Knut Jørgen Labori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6777-7955; OpenAlex author ID A5032849503. Sources: ClinicalTrials.gov.

Their work

Papers
42 (first author 3, last author 9)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
152
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 4 papers, 1 trial · 2017: 3 papers · 2018: 2 papers, 1 trial · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: 5 papers · 2025: 10 papers · 2026: 6 papers

Papers 42

  1. Expression of glycolytic markers in cancer and stromal cells of treatment-naïve and neoadjuvantly treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-026-04478-2↗
  2. Reduced lipid metabolite abundance in human pancreatic cancer and matched serum samples following neoadjuvant FOLFIRINOX treatment. Co-author DOI 10.1007/s11306-025-02388-z↗
  3. Proteomic characterization of primary pancreatic fibroblasts derived from neoadjuvant chemotherapy treated versus treatment-naïve PDAC. Co-author DOI 10.1016/j.jprot.2026.105660↗
  4. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  5. Association between baseline quality of life and survival in patients with non-metastatic, advanced pancreatic cancer. Last author DOI 10.1080/00365521.2025.2585113↗
  6. Beyond Surgery: Does Adjuvant Therapy Still Add Value for Patients With Pancreatic Cancer After Neoadjuvant Treatment? Co-author DOI 10.1245/s10434-026-20630-3↗
  7. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  8. Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreat… Co-author DOI 10.1002/1878-0261.13759↗
  9. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  10. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  11. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  12. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
  13. Anatomical Classification and Staging Systems of Borderline Resectable and Locally Advanced Pancreatic Cancer-A Subgroup Analysis of the NORPACT-2 Trial. Last author DOI 10.1245/s10434-025-17527-y↗
  14. ASO Author Reflections: From BRPC to LAPC-Rethinking Resectability in Pancreatic Cancer. Last author DOI 10.1245/s10434-025-17676-0↗
  15. Prognostic and monitoring potential of circulating tumor DNA in resectable pancreatic cancer. Co-author DOI 10.21037/tgh-24-167↗
  16. Surgical, Histopathological, and Quality of Life Outcomes Following Neoadjuvant Chemotherapy and Pancreatectomy for Borderline Resectable and Locally Advanced … Last author DOI 10.3390/cancers17152505↗
  17. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  18. Performance and safety of diagnostic EUS FNA/FNB and therapeutic ERCP in patients with borderline resectable and locally advanced pancreatic cancer - results f… Last author DOI 10.1080/00365521.2023.2290456↗
  19. Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer - real world data fro… Last author DOI 10.1080/00365521.2024.2373115↗
  20. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
  21. Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1488749↗
  22. Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13344↗
  23. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective coho… Last author DOI 10.1093/bjsopen/zrad137↗
  24. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  25. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  26. Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives. Co-author DOI 10.3389/fsurg.2022.839339↗
  27. Preoperative CTC-Detection by CellSearch® Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer. First author DOI 10.3390/cancers13030485↗
  28. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  29. Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1200/cci.18.00102↗
  30. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  31. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  32. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection. Co-author DOI 10.1016/j.surg.2017.06.009↗
  33. Follow-up After Surgery for Pancreatic Ductal Adenocarcinoma: Steps Toward an International Consensus. Co-author DOI 10.1097/mpa.0000000000000689↗
  34. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a natio… Co-author DOI 10.1186/s12893-017-0291-1↗
  35. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: results of a multicenter cohort study on 196 patients. Co-author DOI 10.1007/s00464-015-4623-x↗
  36. Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2015.09.004↗
  37. Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer. Co-author DOI 10.1080/2162402x.2015.1102828↗
  38. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first … Co-author DOI 10.3109/0284186x.2015.1068445↗
  39. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  40. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Last author DOI 10.1016/j.ejso.2013.02.020↗
  41. Improved survival and quality of life in patients undergoing R1 pancreatic resection compared to patients with locally advanced unresectable pancreatic adenoca… Co-author DOI 10.1016/j.pan.2013.01.003↗
  42. Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer. First author DOI 10.3109/13813455.2011.560609↗

Trials 2

  1. Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) Principal investigator NCT04423731↗
  2. Nordic Pancreatic Cancer Trial (NorPACT) - 1 Principal investigator NCT02919787↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Caroline Sophie Verbeke · 12 shared papers, 2017–2026 · strength 3.52
  2. Ingvild Farnes · 8 shared papers, 2023–2026 · strength 2.32
  3. Ivar P. Gladhaug · 5 shared papers, 2016–2026 · strength 1.25
  4. Manoj Amrutkar · 4 shared papers, 2023–2026 · strength 1.19
  5. Dyre Berg Kleive · 4 shared papers, 2017–2025 · strength 0.77
  6. Pål‐Dag Line · 4 shared papers, 2016–2025 · strength 0.76
  7. Lars Aabakken · 3 shared papers, 2023–2024 · strength 0.71
  8. Jacob Ghotbi · 2 shared papers, 2025 · strength 0.69
  9. Marc G. Besselink · 6 shared papers, 2018–2025 · strength 0.64
  10. Marianne Jensen Hjermstad · 2 shared papers, 2016–2026 · strength 0.49
  11. Svein Olav Bratlie · 3 shared papers, 2023–2025 · strength 0.47
  12. Elin Hegland Kure · 5 shared papers, 2015–2024 · strength 0.46
  13. Gyda G. Christiansen · 1 shared paper, 2026 · strength 0.43
  14. Maia Blomhoff Holm · 1 shared paper, 2026 · strength 0.39
  15. Asif Halimi · 3 shared papers, 2020–2025 · strength 0.38
  16. Hanna E. Seppänen · 2 shared papers, 2024–2025 · strength 0.35
  17. Trond A Buanes · 7 shared papers, 2011–2017 · strength 0.35
  18. Bas Groot Koerkamp · 3 shared papers, 2020–2025 · strength 0.35
  19. Frederik Christiaan Berrevoet · 4 shared papers, 2018–2025 · strength 0.33
  20. Mickaël Lesurtel · 4 shared papers, 2018–2025 · strength 0.33
  21. Marco Del Chiaro · 4 shared papers, 2018–2025 · strength 0.33
  22. Jorg H. Kleeff · 4 shared papers, 2018–2025 · strength 0.33
  23. Giuseppe Fusai · 4 shared papers, 2018–2025 · strength 0.33
  24. Roberto Salvia · 4 shared papers, 2018–2025 · strength 0.33
  25. Ernesto Sparrelid · 2 shared papers, 2024–2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.